Extended Data Fig. 10: Combined TGFβR1i and BMP4 agonist enhances ICB response during chronic LCMV. | Nature Immunology

Extended Data Fig. 10: Combined TGFβR1i and BMP4 agonist enhances ICB response during chronic LCMV.

From: Rebalancing TGFβ1/BMP signals in exhausted T cells unlocks responsiveness to immune checkpoint blockade therapy

Extended Data Fig. 10

(a) Summary bar graphs showing numbers of polyclonal LCMV-specific (CD44hi PD-1+), (b) proliferating (Ki67+) CD44hi PD-1+, (c) Cytolytic (CD44hi Cx3cr1+ PD-1+) and (d) Terminally Exhausted (Tim3+ PD-1 + Cx3cr1-) CD8+ T cells in spleen on day 33 following primary treatment using RepSox, BMP4a, or combined treatment as described in Fig. 8a. (e) Summary dot plot of LCMV viral titers (PFU per ml) in serum from chronically LCMV-infected mice on day 33 following primary treatment. (f) Summary bar graphs showing numbers of proliferating (Ki67 + CD44hi PD-1+) CD8+ T cells, and (g) proliferating P14 (Ki67 + Thy1.1 + GP33-tetramer+) CD8+ T cells in spleen following anti-PD-L1 treatment. All N = 4–6 mice per treatment group per experiment, with data pooled from 2–3 independent experiments. Adjusted P-value ** p < 0.01, *** p < 0.001, **** p < 0.0001; comparisons were made using one-way ANOVA with Tukey’s multiple comparison (panels a–d), or Kruskal-Wallis Test with Dunn’s multiple comparisons (panels f, g) as indicated. Error bars = mean ± SEM.

Source data

Back to article page